|
|
What Patients Need to Know About Tecvayli (teclistamab-cqyv)
In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie thoroughly discusses details on Tecvayli (teclistamab-cqyv)— a new bispecific antibody that was recently approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM). He delves into overall findings from the MajesTEC-1 Trial; in-hospital step-up dose schedule for teclistamab treatments; as well as follow-up treatment and supportive care. Dr. Durie is optimistic that the future is bright in the ever-evolving field of immune therapies. He advises patients to always stay well-informed on new and excellent treatment options to ensure best outcomes.
|
|
|
|
|
|
|
This Week: IMF Virtual Regional Community Workshop (RCW)—Pacific Northwest States
This IMF Virtual Regional Community Workshop (RCW)—Pacific Northwest States—will take place on Saturday, November 19, from 10 a.m. PST to 12:30 p.m. PST. Guest speakers include Craig Cole, MD (Michigan State University, Karmanos Cancer Institute—Detroit, MI) and Amrita Krishnan, MD (City of Hope Comprehensive Cancer Center—Duarte, CA). IMF Nurse Leadership Board (NLB) Member Sandra Rome, RN, MN, AOCN®, CNS will talk about managing side effects and symptoms of myeloma and treatments. After each presentation with the experts, attendees will have ample time to ask questions.
|
|
|
|
|
|
|
CAR T-cell Therapies and Myeloma Patients: A White Paper Published
The IMF hosted two roundtables with myeloma experts—one with nurses and one with physicians—to discuss CAR T-cell therapies and how they will be incorporated into the care of patients with multiple myeloma. This white paper, "Transition of Care Across the CAR T-Cell Therapies Continuum: Implications and Best Practices for the Clinical Team," highlights key aspects of communication between CAR T centers and the community, as well as with the whole healthcare team, with patients, and with their care partners.
|
|
|
|
|
|
|
Watch the Replay: Living Well with Myeloma Webinar
The IMF Living Well with Myeloma Webinar on “Ways to Improve Your Bone Health as a Myeloma Patient” is now available online. The speakers are Jens Hillengass, MD, PhD (Roswell Park Comprehensive Cancer Center—Buffalo, NY) and IMF Nurse Leadership Board (NLB) Member Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic, Taussig Cancer Institute—Cleveland, OH). They review why bone health is so important in myeloma, provide tips on how to live well with myeloma bone disease, give guidelines for physical activity, and more.
|
|
|
|
|
|
|
Watch the Replay: IMF Patient and Family Webinar
The most recent Patient and Family Webinar, “Understanding the New Myeloma Landscape,” is now available online. The speakers for this event include IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie; S. Vincent Rajkumar, MD (Mayo Clinic – Rochester, MN); IMF Nurse Leadership Board (NLB) Member Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic, Taussig Cancer Institute—Cleveland, OH); and Alfred L. Garfall, MD, MS (University of Pennsylvania – Philadelphia, PA). There is a special focus on new immune therapies, including FDA-approved Tecvayli™ (teclistamab-cqyv), as well as available clinical trials.
|
|
|
|
|
|
|
Save the Date: GivingTuesday Is November 29th
GivingTuesday is a global generosity movement, unleashing the power of people and organizations to transform their communities and the world. On November 29th, the IMF will be taking part in GivingTuesday once again, and we hope you will be able to support us to reach our goal of $75,000 in donations. No gift is too small to help impact the lives of myeloma patients. Explore the IMF’s GivingTuesday page and learn how you can contribute as well as use a photo uploader tool on social media platforms to amplify your impact.
|
|
|
|
|
|
Instagram @IMFmyeloma